AU6363999A - Treatment of trauma (i.e. graft rejection) with liposomes containing dna encoding for ctla4ig or for anti-cd40l - Google Patents

Treatment of trauma (i.e. graft rejection) with liposomes containing dna encoding for ctla4ig or for anti-cd40l

Info

Publication number
AU6363999A
AU6363999A AU63639/99A AU6363999A AU6363999A AU 6363999 A AU6363999 A AU 6363999A AU 63639/99 A AU63639/99 A AU 63639/99A AU 6363999 A AU6363999 A AU 6363999A AU 6363999 A AU6363999 A AU 6363999A
Authority
AU
Australia
Prior art keywords
ctla4ig
cd40l
trauma
treatment
dna encoding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU63639/99A
Inventor
Moshe Baru
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Opperbas Holding BV
Original Assignee
Opperbas Holding BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Opperbas Holding BV filed Critical Opperbas Holding BV
Publication of AU6363999A publication Critical patent/AU6363999A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Surgery (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Dispersion Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU63639/99A 1998-10-21 1999-10-20 Treatment of trauma (i.e. graft rejection) with liposomes containing dna encoding for ctla4ig or for anti-cd40l Abandoned AU6363999A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IL12668198A IL126681A0 (en) 1998-10-21 1998-10-21 Treatment of trauma-related conditions
IL126681 1998-10-21
PCT/IL1999/000547 WO2000023115A1 (en) 1998-10-21 1999-10-20 TREATMENT OF TRAUMA (I.E. GRAFT REJECTION) WITH LIPOSOMES CONTAINING DNA ENCODING FOR CTLA4Ig OR FOR ANTI-CD40L

Publications (1)

Publication Number Publication Date
AU6363999A true AU6363999A (en) 2000-05-08

Family

ID=11072042

Family Applications (1)

Application Number Title Priority Date Filing Date
AU63639/99A Abandoned AU6363999A (en) 1998-10-21 1999-10-20 Treatment of trauma (i.e. graft rejection) with liposomes containing dna encoding for ctla4ig or for anti-cd40l

Country Status (5)

Country Link
EP (1) EP1123115A1 (en)
JP (1) JP2002527492A (en)
AU (1) AU6363999A (en)
IL (1) IL126681A0 (en)
WO (1) WO2000023115A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6887471B1 (en) 1991-06-27 2005-05-03 Bristol-Myers Squibb Company Method to inhibit T cell interactions with soluble B7
US7094874B2 (en) 2000-05-26 2006-08-22 Bristol-Myers Squibb Co. Soluble CTLA4 mutant molecules
US20040022787A1 (en) 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
HU227669B1 (en) 2000-07-03 2011-11-28 Bristol Myers Squibb Co Use of soluble ctla4 mutants
ATE359764T1 (en) * 2001-02-22 2007-05-15 Opperbas Holding Bv LIPOSOME-MEDIATED DNA ADMINISTRATION
ATE390931T1 (en) 2001-05-23 2008-04-15 Bristol Myers Squibb Co METHOD FOR PROTECTING AN ALLOGENIC ISLAND TRANSPLANT WITH SOLUBLE CTLA4 MUTATION MOLECULES

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1026253B2 (en) * 1989-03-21 2012-12-19 Vical Incorporated Expression of exogenous polynucleotide sequences in a vertebrate
US5770197A (en) * 1991-06-27 1998-06-23 Bristol-Myers Squibb Company Methods for regulating the immune response using B7 binding molecules and IL4-binding molecules
IL115199A (en) * 1995-09-07 2005-05-17 Opperbas Holding Bv Composition comprising a polynucleic acid molecule in a liposome and method using said composition
US6750334B1 (en) * 1996-02-02 2004-06-15 Repligen Corporation CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor
CA2252055C (en) * 1996-04-11 2007-01-16 The University Of British Columbia Fusogenic liposomes
WO1998030240A1 (en) * 1997-01-10 1998-07-16 Biogen, Inc. Treatment of lupus nephritis with anti-cd40l compounds

Also Published As

Publication number Publication date
EP1123115A1 (en) 2001-08-16
WO2000023115A1 (en) 2000-04-27
JP2002527492A (en) 2002-08-27
IL126681A0 (en) 1999-08-17

Similar Documents

Publication Publication Date Title
AU4950997A (en) Method for preparing malonate methylidene nanoparticles, nanoparticles optionally containing one or several biologically active molecules
AU4311799A (en) Multistage facultative wastewater treatment system
ZA963694B (en) Methods for inhibiting bone loss.
ZA981842B (en) Treated horticultural substrates.
EP0630671A3 (en) Sewage treatment system.
AU1574100A (en) Biological nutrient removal using "the olaopa process"
ZA200007642B (en) Treatment of airborne microorganisms.
AU2277195A (en) Purified dna polymerase from bacillus stearothermophilus
ZA973487B (en) Carbapenem antibacterial compounds, compositions containing such compounds and methods of treatment.
AU7472198A (en) Method for limiting the growth of microorganisms using metal-containing compounds
AU4434799A (en) Modular chemical delivery blocks
WO1994005791A3 (en) Dorsal tissue affecting factor and compositions
AU4428199A (en) Wastewater treatment system
ZA986363B (en) Novel method of treatment.
ZA9711580B (en) Process for the production of purified dimeric bone morphogenetic factors.
ZA964778B (en) Methods for minimizing bone loss.
EP1334981A3 (en) Method for purifying keratinocyte growth factors
AU6363999A (en) Treatment of trauma (i.e. graft rejection) with liposomes containing dna encoding for ctla4ig or for anti-cd40l
AU7096394A (en) Wastewater treatment system
AU6033899A (en) Wastewater treatment system
AU5718396A (en) Wastewater treatment
AUPO684997A0 (en) Polyphenol oxidase genes from banana, tobacco & pineapple
ZA978494B (en) Method for inhibiting the growth of mammalian cells.
AU2668799A (en) Membrane pore inhibiting agents for treating infection
AU1919797A (en) Wastewater treatment system

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase